Theratechnologies Inc
TSX:TH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Ober SA
PAR:ALOBR
|
FR |
|
T
|
TKD Science and Technology Co Ltd
SSE:603738
|
CN |
Theratechnologies Inc
Total Receivables
Theratechnologies Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Theratechnologies Inc
TSX:TH
|
Total Receivables
$11.4m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
13%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Receivables
CA$413.1k
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Receivables
$41.5m
|
CAGR 3-Years
45%
|
CAGR 5-Years
111%
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Receivables
$1.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
16%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Receivables
CA$674.2k
|
CAGR 3-Years
78%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Receivables
$927k
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Theratechnologies Inc
Glance View
Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).
See Also
What is Theratechnologies Inc's Total Receivables?
Total Receivables
11.4m
USD
Based on the financial report for May 31, 2025, Theratechnologies Inc's Total Receivables amounts to 11.4m USD.
What is Theratechnologies Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
13%
Over the last year, the Total Receivables growth was -16%. The average annual Total Receivables growth rates for Theratechnologies Inc have been -4% over the past three years , -1% over the past five years , and 13% over the past ten years .
